Post : Michael Foods Supply Agreement with Aimmune Therapeutic...
December 20, 2018 at 09:51 am EST
Share
- AR201 for Egg Allergy Phase 2 Initiation Planned for 2019 -
- Michael Foods Is the Largest U.S. Processor of Value-Added Eggs -
BRISBANE, Calif.-(BUSINESS WIRE)-Dec. 20, 2018- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the submission of its investigational new drug (IND) application for AR201 for the treatment of egg allergy. The company also announced an exclusive supply agreement for egg protein with Michael Foods, Inc., the largest U.S. processor of value-added eggs. Aimmune expects to initiate a Phase 2 clinical trial of AR201 for the treatment of egg allergy in 2019.
Attachments
Original document
Permalink
Disclaimer
Post Holdings Inc. published this content on 20 December 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 20 December 2018 14:49:14 UTC
Post Holdings, Inc. is a consumer-packaged goods holding company. The Company operates through four segments: Post Consumer Brands, Weetabix, Foodservice and Refrigerated Retail. Post Consumer Brands segment includes North American ready-to-eat (RTE) cereal and Peter Pan nut butter. Weetabix segment includes primarily the United Kingdom (the U.K.) RTE cereal, muesli and protein-based ready-to-drink shakes. The Foodservice segment sells primarily egg and potato products. The Refrigerated Retail segment primarily sells side dishes, egg, cheese and sausage products. The Company also operates a pet food business, which includes the brands, such as Rachael Ray, Nutrish, Natureâs Recipe, 9Lives, Kibbles ân Bits and Gravy Train. This business also includes private-label pet food assets and manufacturing and distribution facilities. The Company also includes two manufacturing and warehousing facilities in Visalia, California.